Search

Displaying results 261 - 270 of 337 in total
  1. Drug

    Rubella virus vaccine

    go.drugbank.com/drugs/DB10317
    ApprovedInvestigational

    Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a comm...

    Mixtures: PROQUAD® ( Measles, Mumps, Rubella AND Varicella (Oka/Merck) Virus Vaccine Live, MSD) LYOPHILIZED VACCINE;
  2. Drug

    Pidotimod

    go.drugbank.com/drugs/DB11364
    Investigational

    Pidotimod is a synthetic dipeptide with immunomodulatory properties.

  3. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    discovery led to the initial development of belzutifan (at the time called PT2977), which was further developed by a spin-off company named Peloton Pharmaceuticals (which itself was eventually acquired by Merck

  4. Drug

    Azetukalner

    go.drugbank.com/drugs/DB21551
    Investigational

    Azetukalner is under investigation in clinical trial NCT05718817 (An Open-label Study of XEN1101 in Epilepsy). Azetukalner has a monoisotopic molecular weight of 368.23 Da.

  5. Drug

    Valinomycin

    go.drugbank.com/drugs/DB14057
    Experimental

    (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.

  6. Drug

    Ebola Zaire vaccine (live, attenuated)

    go.drugbank.com/drugs/DB15595
    ApprovedInvestigational

    [L10866] In 2014, Merck Inc. signed a licensing agreement with NewLink for further development and marketing. … Ervebo, the marketed Ebola virus vaccine by Merck, was first approved by the European Commission in November 2019 after the European Medicines Agency recommended it be licensed.

  7. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

  8. Drug

    αAβ–Gas6

    go.drugbank.com/drugs/DB17069
    Experimental

    αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal a...

  9. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR

  10. Drug

    Davesomeran

    go.drugbank.com/drugs/DB17091
    ApprovedInvestigational

    [L43882] A phase 2 and 3 open-label study in participants 18 years or older who had previously received a two-dose primary series and one booster dose of Moderna COVID-19 Vaccine demonstrated that the